



**JUNE 2018
RIGHTS ISSUE:
INVESTOR
PRESENTATION**

Cofinimmo
together in real estate

* Warning

Investing in the New Shares, the Scrips or trading in the Priority Allocation Rights involves economic and financial risks, as it is the case for every investment in shares. Prospective investors must consider, when taking their investment decision, that they may lose all or part of their investment. See Section "Risk factors" of the Registration Document and Section 1 "Risk Factors" of the Securities Note for a discussion of the factors that should be carefully considered in connection with an investment in the New Shares, the Scrips and trading in the Priority Allocation Rights.

Potential investors must be able to bear the economic risk of investing in the New Shares and must be able to cover a total or partial loss of their investment

Potential investors must be aware that the Priority Allocation Rights relating to Ordinary Shares and the Priority Allocation Rights relating to Preferential Shares have a different treatment. The Priority Allocation Rights relating to Ordinary Shares will trade on the regulated market of Euronext Brussels while the Priority Allocation Rights relating to Preferential Shares will not be traded on any stock exchange and may only be transferred over the counter.

* Disclaimer

This presentation has been prepared by the management of Cofinimmo SA/NV, Belgian public real estate investment company (“Cofinimmo” or the “Company”), solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this document and any opinions expressed in relation thereto are subject to change without notice. The presentation comprises written material/slides which provide information on the Company and its subsidiaries. Save where otherwise indicated, the Company is the source of the content of this Presentation. Notwithstanding the fact that care has been taken to ensure that the facts stated in this Presentation are accurate, and that the opinions expressed are fair and reasonable, the Company gives no representation or warranty, express or implied, relating to the fairness, accuracy, reasonableness or completeness of the information contained in this Presentation. The Securities Note (including the documents incorporated by reference therein), the Registration Document (including the documents incorporated by reference therein) and the Summary constitute the Prospectus. The English version of the Securities Note and of the Summary were approved by the FSMA on 19 June 2018, in accordance with Article 23 of the Act of 16 June 2006. The approval of the FSMA does not imply an assessment of the appropriateness or quality of the Offering, nor of the condition of the Company. The prospectus is, subject to the usual limitations, available on the Company’s website. An investment in shares entails significant risks. The investors are encouraged to read the Prospectus and in particular the risk factors set out therein. Any decision to invest in securities in the framework of the offering must be based on all information provided in the Prospectus, and any supplements thereto, as the case may be. This Presentation does not contain all the information that may be important for investors.

This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

* Disclaimer (continued)

This Presentation and the information contained herein are not for distribution in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"), Australia, Canada or Japan or any other state or jurisdiction which such release, publication or distribution would be unlawful. This Presentation does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The securities of Cofinimmo SA have not been and will not be registered under the U.S. Securities Act of 1933 (the "Securities Act") and may not be offered or sold within the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. No public offering of the securities is being made into the United States. In addition, in the United Kingdom, this Presentation is directed at and for distribution only to Qualified Investors who are (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and other persons to whom this Presentation may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

No announcement or information regarding the capital increase by Cofinimmo with shares in Cofinimmo may be disseminated to the public in jurisdictions other than Belgium where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the offering of shares in any jurisdiction outside of Belgium where such steps would be required. The issue or sale of shares, and the subscription for or purchase of shares, are subject to special legal or statutory restrictions in certain jurisdictions. Cofinimmo is not liable if these restrictions are not complied with by any person.

A prospectus has been published in relation to the offering of the securities referred to in this Presentation. A copy of the prospectus is available from 20 June 2018. Investors may not accept an offer of securities referred to herein, nor acquire such securities, unless on the basis of information contained in the prospectus. This Presentation cannot be used as basis for any investment agreement or decision

* Table of contents

Use of proceeds	p. 7
Track-record	p. 19
Key financials	p. 23
Transaction details	p. 26
2018 Forecast	p. 32
Appendices	p. 35

* Management team



Jean-Pierre Hanin
CEO & Managing Director
(as from 09.05.2018)



Jean Kotarakos
CFO (as from 01.06.2018)



Françoise Roels
Secretary General and Group Counsel


USE OF PROCEEDS

Torenzicht Medical Office Building – Eemnes (NL)


Cofinimmo
together in real estate

* Acceleration of healthcare investments: financing of updated 2018 pipeline

**2018 Pipeline
published on 08.02.2018:
68 million EUR**




**2018 Updated pipeline:
358 million EUR**



* Breakdown of 2018 investments (358 million EUR)

Investments realised, committed and under due diligence for 2018: 358 million EUR



* Breakdown of 2018 realised investments (211 million EUR)

Healthcare real estate: 199 million EUR

- Acquisitions in Germany: 189 million EUR
Portfolio of 17 nursing & care homes (cfr. infra), Niebüll & Langelsheim
- Reconversions and renovations/extensions in Belgium: 6 million EUR
Woluwe 106-108 (Brussels), De Notelaer (Keerbergen), Zonneweelde (Rijmenam) & Zonnewende (Aartselaar)
- Renovation/extension in France: 3 million EUR
Domaine de Vontes (Esvres-sur-Indre)
- New construction in the Netherlands: 1 million EUR
Gorinchem

Offices: 11 million EUR

- Reconstruction of Quartz building: 2 million EUR
- Reconstruction of Belliard 40 building: 5 million EUR
- Other renovation or reconversion projects: 4 million EUR

Property of distribution networks: 1 million EUR



Pro Forma **debt ratio** as at the launch of this rights issue: **46 %**

* Breakdown of 2018 committed investment pipeline (55 million EUR)

Healthcare real estate: 42 million EUR

- Acquisitions and renovations/extensions in Germany: 31 million EUR
Bad Sassendorf, Riesa, Chemnitz & Bismarckpark (Gelsenkirchen)
- Reconversions and renovations/extensions in Belgium: 6 million EUR
Woluwe 106-108, De Notelaer (Keerbergen), Zonneweelde (Rijmenam) & Zonnewende (Aartselaar)
- Renovation/extension in France: 4 million EUR - Domaine de Vontes (Esvres-sur-Indre)
- New construction in the Netherlands: 1 million EUR - Gorinchem

Offices: 8 million EUR

- Reconstruction of Quartz building: 3 million EUR
- Reconstruction of Belliard 40 building: 2 million EUR
- Other renovation or reconversion projects: 3 million EUR

Property of distribution networks: 5 million EUR



Forecasted **debt ratio** at end 2018 after financing of the committed pipeline before impact of this rights issue : **45 %** / after impact of this rights issue: **41 %**

Forecasted **debt ratio** at end 2018 after financing of the committed pipeline and the investments under due diligence before impact of this rights issue : **46 %** / after impact of this rights issue: **43 %**

* Acquisition of a German nursing home portfolio

Agreement for the acquisition of a portfolio of 17 nursing & care homes in Germany

Via the acquisition of 94.9 % of the shares of 14 companies, on 15.06.2018

Companies bought own together 17 nursing & care homes in Germany

16 assets in operation and 1 asset under construction (delivery expected in 4Q2018)

Total above-ground surface area : approx. 75,000 m²

Price of the assets taken into account in the calculation of the share price: **172 million EUR**

Long-term leases signed with the German operating Group Stella Vitalis

Firm lease length of 30 years

Initial gross rental yield of approx. 5.5 %



Haus Hüttener Berge nursing & care home - Ascheffel (DE)

* High-quality assets

	Name of the facility	Land	City	Year of construction	In operation/ Under construction	Number of beds
1.	Seniorenzentrum an der Seestraße in Erftstadt-Liblar	NW	Erftstadt	2008	In operation	130
2.	Stella Vitalis Seniorenzentrum Bochum	NW	Bochum	2010	In operation	92
3.	Stella Vitalis Seniorenzentrum Haan	NW	Haan	2010	In operation	91
4.	Pflege Plus + Seniorenzentrum Bottrop	NW	Bottrop	2008	In operation	80
5.	Stella Vitalis Seniorenzentrum Alsdorf	NW	Alsdorf	2010	In operation	90
6.	Pflege Plus + Seniorenzentrum Duisburg	NW	Duisburg	2007	In operation	80
7.	Seniorenzentrum Sonnenhof & Rosengarten	SH	Lunden	1999	In operation	94
8.	Seniorenzentrum Haus Hüttener Berge	SH	Ascheffel	1991	In operation	80
9.	Seniorenzentrum Haus am Mühlenstrom	SH	Schafflund	1997	In operation	78
10.	Seniorenzentrum Haus am Lecker Mühlenstrom	SH	Leck	1999	In operation	73
11.	Landhuus Viöl	SH	Viöl	2002	In operation	60
12.	Stella Vitalis Seniorenzentrum Weilerswist	NW	Weilerswist	2016	In operation	80
13.	Stella Vitalis Seniorenzentrum Weil am Rhein	BW	Weil am Rhein	2015	In operation	100
14.	Stella Vitalis Seniorenzentrum Goslar	NI	Goslar	2014	In operation	99
15.	Stella Vitalis Seniorenzentrum Friedrichstadt	SH	Friedrichstadt	2017	In operation	90
16.	Seniorenzentrum Gelsenkirchen	NW	Gelsenkirchen	2017	In operation	80
17.	Stella Vitalis Seniorenzentrum Swisttal	NW	Swisttal	2018	Under construction	80
Total						1,477

* Asset locations



Weil am Rhein home - Weil am Rhein (DE)



Haus am Mühlenstrom home - Schafflund (DE)



Weilerswist home - Weilerswist (DE)

* Long-term 'Dach und Fach' leases

17 assets let to Stella Vitalis

New leases signed at the closing

Duration: **30 years** (firm)

All leases are 'Dach und Fach'

Maintenance of roof and building structure to be borne by Cofinimmo

All leases will be indexed

Based on the German consumer price index



An der Seestraße nursing & care home - Erfstadt (DE)

* A new tenant-operator

Stella Vitalis

- Operator specialised in care & housing of elderly people
- Active since 2006, covering large parts of Western Germany
- Operating over 1,650 beds in approx. 20 assets
- Recognized for excellence and high quality
- Strong desire to grow through acquisitions and built-to-suit developments




Alsdorf nursing & care home - Alsdorf (DE)



Acceleration of investments in healthcare real estate

Cofinimmo comes closer to its target of 50% of its global portfolio invested in healthcare real estate before end 2019

Historical portfolio breakdown by segment (in fair value)




(* Pro forma taking into account the breakdown at 31.03.2018 and the acquisitions which took place after 31.03.2018 (Niebüll + Langelsheim + portfolio of 17 nursing and care homes).

* Further diversification of Cofinimmo's healthcare portfolio

Improved risk profile in terms of country exposure

Pro forma healthcare portfolio breakdown by country
(in fair value)



■ Belgium ■ France
■ Germany ■ Netherlands

Strengthened position on the German healthcare real estate market

- *Pro forma* fair value of Cofinimmo's German healthcare portfolio: **330 million EUR**
- Number of sites: **28**, of which:
 - 24 nursing & care homes;
 - 2 revalidation clinics;
 - 2 sport & wellness centres.
- Number of operator-tenants: **8**


TRACK-RECORD
until 31.03.2018

Noordduin nursing & care home – Koksijde (BE)


Cofinimmo
together in real estate

* Portfolio breakdown overview

Portfolio breakdown per segment – in fair value




Portfolio breakdown per country – in fair value



* Investments/divestments overview


Healthcare real estate:

Net investments: +1,444 million EUR



Offices:


Net divestments: -669 million EUR






Strong track-record reflected in various KPIs


Long residual lease term – high visibility of income



Gradual yield compression



High occupancy



KEY FINANCIALS

* Key financials

Net result from core activities (EPRA Earnings): 6.53 EUR/share

	(x 1,000,000 EUR)		Per share* (EUR)	
	31.12.2016	31.12.2017	31.12.2016	31.12.2017
Operating result before result on portfolio	172,079	172,047	8.19	8.07
Net result from core activities – Group share	134,260	139,090	6.40	6.53
Result on financial instruments – Group share	-38,850	1,063	-1.85	0.05
Result on the portfolio – Group share	1,983	-2,791	0.09	-0.13
Net result – Group share	97,393	137,362	4.64	6.45

* Number of shares entitled to share in the result of the period : 20,986,326 at 31.12.2016 vs. 21,308,702 at 31.12.2017.

* EPRA financial KPI's on 31.12.2017

	31.12.2016	31.12.2017
EPRA Earnings per share (in EUR)	6.40	6.53
EPRA Diluted Earnings per share (in EUR)	6.39	6.52

	31.12.2016	31.12.2017
EPRA Net Asset Value (NAV) per share (in EUR)	92.76	93.26
EPRA Adjusted Net Asset Value (NNNAV) per share (in EUR)	90.81	91.24
EPRA Net Initial Yield (NIY)	6.0 %	5.6 %
EPRA Vacancy Rate	5.6 %	5.5 %
EPRA Cost ratio (cost of vacancy excluded)	19.5 %	19.8 %

Conversion of IFRS NAV to EPRA (NN)NAV (31.12.2017)

	(x 1,000,000 EUR)	Per share (EUR)
NAV per financial statements	1,903.2	89.31
Fair value of financial leases	43.3	-
EPRA NNNNAV	1,946.5	91.24
Fair value of financial instruments	47.1	2.21
Deferred taxes	40.1	1.88
Goodwill as a result of deferred taxes	-44.2	-2.07
EPRA NAV	1,989.5	93.26

TRANSACTION DETAILS

Oisterwijk Kliniek Medical Office Building – Oisterwijk (NL)

Cofinimmo
together in real estate

* Transaction details (1)

Listing place

- Euronext Brussels

Transaction size

- Up to 155 million EUR, represented by 1,642,374 new shares

Transaction structure

- Priority Allocation Rights for existing shareholders
- Private placement of non-exercised Priority Allocation Rights after the subscription period

Subscription ratio

- 1 new share for 13 Priority Allocation Rights (represented by coupon nr. 32 for the Ordinary Shares, coupon nr. 20 for the Preferential Shares 1 and coupon nr. 19 for the Preferential Shares 2)

Subscription price

- 94.50 EUR per new share

Subscription period

- Subscription period with Priority Allocation Rights: 21.06.2018 – 27.06.2018
- Private placement of scrips (non-exercised rights): 28.06.2018

Dividend

- The New Shares will be entitled to the dividend of the current financial year (started on 1 January 2018) pro rata temporis as from the Closing Date (i.e. the issue date of the New Shares) until 31 December 2018. The New Shares will therefore be issued ex-coupon nr. 33, i.e. the coupon representing the right to a dividend for the current financial year (started on 1 January 2018) until the day before the Closing Date.

Payment & settlement

- Payment and delivery of the new shares: 02.07.2018
- Listing and settlement: 02.07.2018

* Transaction details (2)

Listing details

- The priority allocation rights relating to ordinary shares will trade on the regulated market of Euronext Brussels whereas the priority allocation rights relating to preferential shares will not be traded on any stock exchange and may only be transferred over the counter.

Applicable law

- The new shares will be issued in accordance with Belgian law. The offering is subject to Belgian law.

Charges

- Investors will not be charged any costs for subscribing to the offering by the issuer nor the underwriters. Investors must inform themselves about costs their financial institutions might charge to them.

Related documents

- A prospectus (composed of the Registration Document, the Securities note and the Summary) has been published in relation to the offering of the securities referred to in this document. A free copy of the prospectus is available as from 20.06.2018 at Cofinimmo's registered offices, Boulevard de la Woluwe 58, 1200 Brussels or on the Cofinimmo website (www.cofinimmo.be). Investors are advised to read the prospectus before investing. This presentation cannot be used as basis for any investment agreement or decision.

Syndicate

- Joint Global Coordinators: BNP Paribas Fortis and ING Belgium
- Joint Bookrunners: BNP Paribas Fortis, ING Belgium, Bank Degroof Petercam, Joh. Berenberg, Gossler & Co, KBC Securities and Société Générale

* Main risks relating to the shares

- *The market price of the Priority Allocation Rights or the Shares could be negatively affected by sales of substantial numbers of Priority Allocation Rights or Shares in the public markets.*
- *The market price of the Shares may be volatile and could decrease, which may lead to the shareholders not being able to sell their Shares at a price equal to or above the Issue Price or a price which is reasonable. A substantial decline in the market price of the Shares may result in the Priority Allocation Rights becoming worthless.*
- *The New Shares may not be traded actively, and there is no assurance that the Offering will improve the trading activity.*
- *There is no assurance that a trading market will develop for the Priority Allocation Rights relating to Ordinary Shares, and if a market does develop, the market price for the Priority Allocation Rights relating to Ordinary Shares may be subject to greater volatility than the market price for the Shares.*
- *The Priority Allocation Rights relating to Preferential Shares will not be traded on any stock exchange and there will not be an organised market for such rights during the Priority Rights Subscription Period. Hence holders of Priority Allocation Rights relating to Preferential Shares may therefore have difficulties to sell their rights or to acquire Priority Allocation Rights of the same class of Preferential Shares*
- *Existing shareholders will experience dilution as a result of the Offering if they do not or could not exercise their Priority Allocation Rights in full.*
- *Failure to exercise Priority Allocation Rights during the Rights Subscription Period will result in such Priority Allocation Rights becoming null and void.*
- *Investors outside of Belgium may be restricted from participating in this Priority Rights Offering, and may be subject to dilution or other financial adverse consequences (notice for non-Belgian resident investors.*
- *Investors should not place undue reliance on the forward-looking forecast with respect to the financial year 2018, as such information could differ materially from the actual results for the period.*
- *Any sale, purchase or exchange of New Shares may become subject to the Financial Transaction Tax.*

* Main risks relating to the issuer

- *Reduced solvency/bankruptcy of clients-tenants*

Potential impact: 1. Unexpected rental vacancy. 2. Negative impact on rental income: rents revised downwards, granting of rent-free periods and incentives, higher marketing expenses to attract new tenants. 3. Negative impact on the value of the property portfolio.

- *Inappropriate choice of investments or (re)developments projects*

Potential impact: 1. Negative impact on the Group's income potential. 2. Mismatch with market demand and vacancy. 3. Expected yields not achieved.

- *Negative change in the fair value of the properties*

Potential impact: 1. Negative impact on the net result, the net asset value and the debt ratio. 2. If the cumulative changes in the properties' fair value exceed the distributable reserves, partial or total inability to pay a dividend.

- *Unfavourable changes in the RREC, SIIC or FBI regimes (or in their application by the public authorities)*

Potential impact: Negative impact on the net result and on the net asset value.

- *Changes in town-planning legislation (e.g. the procedure for listing or protecting a building)*

Potential impact: 1. Negative impact on the value of a building. 2. Increase in the costs incurred to maintain a building in operation. 3. Negative impact on the Group's ability to operate a building.

- *Changes in social security regimes*

Potential impact: Negative impact on the solvency of healthcare operators

* Timetable

Event	Date
Board meeting deciding rights issue terms and pricing	18.06.2018
Announcement of rights issue terms	20.06.2018
Detachment of the 2 coupons: <ul style="list-style-type: none"> • Priority allocation rights (for both Preferential Shares and the Ordinary Shares) • Pro rata 2018 dividend 	20.06.2018
Subscription period for existing shareholders	21.06.2018 to 27.06.2018 (included)
Trading of the priority allocation rights of the Ordinary Shares on Euronext Brussels.	
Announcement of the results of the rights offering	28.06.2018
Scrip placement of the unexercised preferential rights to institutional investors through an accelerated bookbuilding	28.06.2018
Announcement of the results of the scrip placement	28.06.2018
Results of the Offering	28.06.2018
Settlement and listing of new shares	02.07.2018

2018 FORECAST

Cofinimmo
together in real estate

Caux du Littoral nursing & care home – Néville (FR)

* Forward-looking statements

The Prospectus includes forward-looking statements. By their nature, forward-looking statements are subject to inherent risks and uncertainties, both general and specific, and the predictions, forecasts, projections and other forward-looking statements contained in the Prospectus could be materially different from what actually occurs in the future. In addition, the Prospectus contains estimates of growth in the markets in which the Issuer operates that have been obtained from independent, third party studies and reports. These estimates assume that certain events, trends and activities will occur. Although the Issuer believes that these estimates are generally indicative of the matters reflected in those studies and reports, these estimates are also subject to risks and uncertainties and investors are cautioned to read these estimates in conjunction with the rest of the disclosure in the Prospectus, particularly "Risk Factors" in the Registration Document and Section 1, "Risk Factors" in this Securities Note.

Although the Issuer believes that its expectations with respect to forward-looking statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations at the date of the Prospectus, Existing Shareholders and prospective investors are cautioned that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. Some of these factors are discussed in Section 1, "Risk Factors" and elsewhere in the Prospectus.

The forward-looking statements contained in the Prospectus speak only at the date of the Prospectus or, if obtained from third party studies or reports, the date of the corresponding study or report and are expressly qualified in their entirety by the cautionary statements included in the Prospectus. Without prejudice to the Issuer's obligations under Belgian law in relation to disclosure and ongoing information and in relation to the publication of a Supplement to the Prospectus, the Issuer does not undertake any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in the Prospectus might not occur.

* Updated 2018 forecast

Net result from core activities – Group share (EPRA Earnings): 6.51 EUR/share

Gross dividend: 5.50 EUR/ordinary share

	2017 Actual	2018 Forecast published on 08.02.2018	Updated 2018 post-money forecast
Net result from core activities per share (in EUR)	6.53	6.54	6.51
Gross dividend per ordinary share (in EUR)	5.50	5.50	5.50
Number of shares entitled to share in the result of the period	21,308,702	21,308,702	22,132,138*
Pay-out ratio on net result from core activities	84.2 %	84.1 %	84.5 %
Debt ratio	43.8 %	44.4 %	41.1 %

* 21,308,702 as at 31.03.2018 + 823,436 new shares.

(The 1,642,374 new shares to be issued will be entitled to share in the 2018 result as from 02.07.2018 only.)



This forecast does **not** take into account the pipeline of investments planned for 2018 which are under due diligence and for which the Issuer has not committed itself.

APPENDICES

Henri Dunant nursing & care home – Brussels (BE)

Cofinimmo
together in real estate

* 2018 Income statement forecast (x 1,000,000 EUR)

Consolidated income statement	Actual	Forecast published on 08.02.2018	Updated 'post-money' forecast
	2017	2018	2018
Rental income, net of rental-related expenses	204	203	210
Writeback of lease payments sold and discounted (non-cash item)	12	14	9
Rental-related expenses and taxes on rented properties not recovered	-1	-2	-2
Taxes on properties under redevelopment not recovered	-2	-5	-5
Redecoration costs, net of tenant compensation for damages	-3	-2	-2
Property result	210	208	210
Technical costs	-5	-7	-7
Commercial costs	-2	-2	-2
Taxes and charges on unlet properties	-5	-4	-4
Property result after direct property costs	198	195	197
Corporate management costs	-26	-25	-25
Operating result (before result on portfolio)	172	170	172
Financial income	6	5	9
Net interest charges	-30	-31	-31
Other financial charges	0	0	0
Share in the net result from core activities of associated companies and joint ventures	0	0	0
Taxes	-4	0	-1
Net result from core activities	144	144	149
Minority interests related to the net result from core activities	-5	-5	-5
Net result from core activities - Group share	139	139	144
Total number of shares used to calculate the result per share	21,308,702	21,308,702	22,132,138 (prorata temporis)

* This forecast does **not** take into account the pipeline of investments planned for 2018 which are under due diligence and for which the Issuer has not committed itself.

* 31.12.2018 Balance sheet forecast (x 1,000,000 EUR)

Consolidated balance sheet	Actual	2018 Forecast published on 08.02.2018	Updated 2018 'post-money' forecast
	31.12.2017	31.12.2018	31.12.2018
ASSETS			
NON-CURRENT ASSETS	3,689	3,754	3,833
Goodwill	85	85	85
Investment properties	3,507	3,554	3,651
Finance lease receivables	85	103	85
Other non-current assets	5	4	4
Participations in associated companies and joint ventures	7	8	8
CURRENT ASSETS	94	94	97
Assets held for sale	1	0	0
Finance lease receivables	2	2	2
Cash and cash equivalents	23	23	23
Other current assets	68	69	72
TOTAL ASSETS	3,783	3,848	3,930
SHAREHOLDERS' EQUITY and LIABILITIES	31.12.2017	31.12.2018	31.12.2018
SHAREHOLDERS' EQUITY	1,987	2,000	2,176
SHAREHOLDERS' EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF PARENT COMPANY	1,903	1,915	2,087
MINORITY INTERESTS	84	85	89
LIABILITIES	1,796	1,848	1,754
NON-CURRENT LIABILITIES	1,223	1,226	1,125
Non-current financial debts	1,113	1,116	1,017
Other non-current financial liabilities	110	110	108
CURRENT LIABILITIES	573	622	629
Current financial debts	463	510	508
Other current financial liabilities	110	112	121
TOTAL SHAREHOLDERS' EQUITY and LIABILITIES	3,783	3,848	3,930

* This forecast does **not** take into account the pipeline of investments planned for 2018 which are under due diligence and for which the Issuer has not committed itself.

* Prospectus

The Prospectus will be made available to investors as from 20 June 2018 at no cost at the registered offices of the Issuer. The Prospectus will also be made available to investors at no cost from BNP Paribas Fortis SA/NV at +32 (0)2 433 41 13 and on its websites (www.bnpparibasfortis.be/sparenenbeleggen (Dutch and English) and www.bnpparibasfortis.be/epargneretplacer (French and English)), from ING Belgium SA/NV at +32 (0)2 464 60 02 (French), +32 (0)2 464 60 01 (Dutch) and +32 (0)2 464 60 04 (English) and on its websites (www.ing.be/equitytransactions (English), www.ing.be/transactionsdactions (French) and www.ing.be/aandelentransacties (Dutch)), from Société Générale at Park Atrium, 11 Rue des colonies, 1000 Brussels, Belgium, from Bank Degroof Petercam SA/NV at +32 2 287 97 78 (French, Dutch and English) and on its websites (http://www.degroofpetercam.be/nl/nieuws/cofinimmo_2018 (Dutch), http://www.degroofpetercam.be/fr/actualite/cofinimmo_2018 (French) and http://www.degroofpetercam.be/en/news/cofinimmo_2018 (English)), from KBC Securities NV at +32 2 429 37 05 (Dutch, French and English), KBC Bank NV at +32 3 283 29 70 (Dutch, French and English), CBC Banque SA at +32 800 90 020 (French and English) and via Bolero at number +32 800 628 16 (Dutch, French and English) and on its websites (<https://www.kbcsecurities.com/prospectus-documents-overviews/prospectus-overview>, www.kbc.be/corporateactions, www.cbc.be/corporateactions and <https://www.bolero.be>) and from Joh. Berenberg, Gossler & Co KG, Hamburg at Neuer Jungfernstieg 20, D-20354 Hamburg/Germany. Subject to certain conditions, this Prospectus is also available on the internet at the following website: www.cofinimmo.com.

Any decision to invest in the New Shares, the Scrips or trading in the Priority Allocation Rights should be based on an exhaustive analysis of the Prospectus by the investor.

* Contact

FOR MORE INFORMATION CONTACT:

Ellen Grauls

Head of External Communication & Investor Relations
T +32 (0)2 373 94 21
egraults@cofinimmo.be



Benoît Mathieu

Investor Relations Officer
T +32 (0)2 373 60 42
bmathieu@cofinimmo.be



www.cofinimmo.com